ES2114570T3 - Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. - Google Patents

Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.

Info

Publication number
ES2114570T3
ES2114570T3 ES92922216T ES92922216T ES2114570T3 ES 2114570 T3 ES2114570 T3 ES 2114570T3 ES 92922216 T ES92922216 T ES 92922216T ES 92922216 T ES92922216 T ES 92922216T ES 2114570 T3 ES2114570 T3 ES 2114570T3
Authority
ES
Spain
Prior art keywords
prostacicline
ultrasonics
inhibition
rays
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922216T
Other languages
English (en)
Spanish (es)
Inventor
Rainer Klopp
Wolfgang Niemer
Wolfgang Schippel
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2114570T3 publication Critical patent/ES2114570T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
ES92922216T 1991-10-22 1992-10-22 Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. Expired - Lifetime ES2114570T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135193A DE4135193C1 (enExample) 1991-10-22 1991-10-22

Publications (1)

Publication Number Publication Date
ES2114570T3 true ES2114570T3 (es) 1998-06-01

Family

ID=6443371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922216T Expired - Lifetime ES2114570T3 (es) 1991-10-22 1992-10-22 Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.

Country Status (11)

Country Link
US (1) US5814301A (enExample)
EP (1) EP0609336B1 (enExample)
JP (1) JPH07500585A (enExample)
AT (1) ATE162718T1 (enExample)
CA (1) CA2121838A1 (enExample)
DE (2) DE4135193C1 (enExample)
DK (1) DK0609336T3 (enExample)
ES (1) ES2114570T3 (enExample)
GR (1) GR3026324T3 (enExample)
PT (1) PT100997B (enExample)
WO (1) WO1993007875A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
PL328199A1 (en) * 1996-01-25 1999-01-18 Schering Ag Improved concentrated intravascular injection and infusion solutions
KR100638684B1 (ko) * 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US20020147223A1 (en) * 1999-06-14 2002-10-10 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
WO2000076496A1 (en) * 1999-06-14 2000-12-21 Toray Industries, Inc. Tumor tissue accumulation enhancers for drugs
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ES2670872T3 (es) * 2003-05-22 2018-06-01 United Therapeutics Corporation Polimorfo de una sal de dietanolamina de treprostinil
CA2562614C (en) * 2004-04-12 2013-09-17 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
KR20240119159A (ko) * 2018-09-14 2024-08-06 파모사 바이오팜 인코포레이티드 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3204443A1 (de) * 1982-02-08 1983-08-18 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3448257C2 (en) * 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
SE459806B (sv) * 1987-11-23 1989-08-07 Nils Enar Nilsson Anordning foer foerflyttning av en foersta del relativt en andra del
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤

Also Published As

Publication number Publication date
US5814301A (en) 1998-09-29
WO1993007875A1 (de) 1993-04-29
DK0609336T3 (da) 1998-09-21
CA2121838A1 (en) 1993-04-29
PT100997B (pt) 1999-10-29
DE4135193C1 (enExample) 1993-03-11
PT100997A (pt) 1994-01-31
ATE162718T1 (de) 1998-02-15
DE59209175D1 (de) 1998-03-05
GR3026324T3 (en) 1998-06-30
JPH07500585A (ja) 1995-01-19
EP0609336B1 (de) 1998-01-28
EP0609336A1 (de) 1994-08-10

Similar Documents

Publication Publication Date Title
NO2005019I2 (no) Metylaminolevulinat, eventuelt i form av et salt, fortrinnsvis metylaminolevulinat-hydroklorid
FI943948A0 (fi) Heterosykliset hiilihappojohdannaiset
NO952533D0 (no) Vandige, injiserbare blandinger nyttige for röntgendiagnose, omfattende joderte aromatiske forbindelser anvendt som röntgenstrålekontrastmedium
DE69401584D1 (de) Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese
DE69216221D1 (de) Verbindungen mit guanidin-struktur und diese enthaltende pharmazeutische zusammensetzungen
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
BR9507231A (pt) Uso de derivados de ácido carboxílico para a produção de drogas
PT1007023E (pt) Derivados de 1-¬1-(4-clorofenil)ciclobutil|-3-metil-butil amina para reducao dos niveis de acido urico em seres humanos
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
BR0011440A (pt) Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides
NO950177L (no) Farmakologisk aktive erivater
ITMI910658A1 (it) N-(4, 5-diidrossi-e 4, 5, 8-triidrossi-9, 10-diidro-9, 10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
DK0678089T3 (da) N-Acylpyrrolidiner og lægemidler til behandling eller forebyggelse af cholecystokinin- og gastrin-relaterede forstyrrelser
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
DK0664811T3 (da) Gestagent aktive 4-estrener med bro mellem stillingerne 19,11
DK0569411T3 (da) Acylaminoalkylidenhydroxybiphosphonsyrer anvendelige til behandling af osteoartikulære sygdomme
ATE160772T1 (de) Entzündungshemmende makrolactame (cyclamenol)
SE7700200L (sv) Forfarande for framstellning av karboxylsyraderivat av indan med anti-inflammatoriesk, analgetisk och antipyretisk aktivitet
TH177262A (th) สารผสม และฤทธิ์ต้านไวรัสของอนุพันธ์แอซาอินโดลออกโซแอซีติกพิเพอแรซีนที่ถูกแทนที่

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 609336

Country of ref document: ES